1nu6 › Citations

Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV.

Thoma R, Löffler B, Stihle M, Huber W, Ruf A, Hennig M
Structure 11 947-59 (2003)
Cited: 105 times
EuropePMC logo PMID: 12906826

Abstract

Inhibition of dipeptidyl peptidase IV (DPP-IV), the main glucagon-like peptide 1 (GLP1)-degrading enzyme, has been proposed for the treatment of type II diabetes. We expressed and purified the ectodomain of human DPP-IV in Pichia pastoris and determined the X-ray structure at 2.1 A resolution. The enzyme consists of two domains, the catalytic domain, with an alpha/beta hydrolase fold, and a beta propeller domain with an 8-fold repeat of a four-strand beta sheet motif. The beta propeller domain contributes two important functions to the molecule that have not been reported for such structures, an extra beta sheet motif that forms part of the dimerization interface and an additional short helix with a double Glu sequence motif. The Glu motif provides recognition and a binding site for the N terminus of the substrates, as revealed by the complex structure with diprotin A, a substrate with low turnover that is trapped in the tetrahedral intermediate of the reaction in the crystal.

Articles - 1nu6 mentioned but not cited (7)

  1. Protein subunit interfaces: heterodimers versus homodimers. Zhanhua C, Gan JG, Lei L, Sakharkar MK, Kangueane P. Bioinformation 1 28-39 (2005)
  2. Analysis on conservation of disulphide bonds and their structural features in homologous protein domain families. Thangudu RR, Manoharan M, Srinivasan N, Cadet F, Sowdhamini R, Offmann B. BMC Struct Biol 8 55 (2008)
  3. The good, the bad and the dubious: VHELIBS, a validation helper for ligands and binding sites. Cereto-Massagué A, Ojeda MJ, Joosten RP, Valls C, Mulero M, Salvado MJ, Arola-Arnal A, Arola L, Garcia-Vallvé S, Pujadas G. J Cheminform 5 36 (2013)
  4. Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays. Guasch L, Ojeda MJ, González-Abuín N, Sala E, Cereto-Massagué A, Mulero M, Valls C, Pinent M, Ardévol A, Garcia-Vallvé S, Pujadas G. PLoS One 7 e44971 (2012)
  5. An Integrated Peptidomics and In Silico Approach to Identify Novel Anti-Diabetic Peptides in Parmigiano-Reggiano Cheese. Martini S, Solieri L, Cattivelli A, Pizzamiglio V, Tagliazucchi D. Biology (Basel) 10 563 (2021)
  6. Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor. Nojima H, Kanou K, Terashi G, Takeda-Shitaka M, Inoue G, Atsuda K, Itoh C, Iguchi C, Matsubara H. BMC Struct. Biol. 16 11 (2016)
  7. Application of a Combined Peptidomics and In Silico Approach for the Identification of Novel Dipeptidyl Peptidase-IV-Inhibitory Peptides in In Vitro Digested Pinto Bean Protein Extract. Martini S, Cattivelli A, Conte A, Tagliazucchi D. Curr Issues Mol Biol 44 139-151 (2021)


Reviews citing this publication (22)

  1. The metabolic serine hydrolases and their functions in mammalian physiology and disease. Long JZ, Cravatt BF. Chem. Rev. 111 6022-6063 (2011)
  2. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Deacon CF, Ahrén B, Holst JJ. Expert Opin Investig Drugs 13 1091-1102 (2004)
  3. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Regul. Pept. 128 159-165 (2005)
  4. Survey of the year 2003 commercial optical biosensor literature. Rich RL, Myszka DG. J. Mol. Recognit. 18 1-39 (2005)
  5. A new strategy for improved secondary screening and lead optimization using high-resolution SPR characterization of compound-target interactions. Huber W. J. Mol. Recognit. 18 273-281 (2005)
  6. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. McIntosh CH, Demuth HU, Kim SJ, Pospisilik JA, Pederson RA. Int. J. Biochem. Cell Biol. 38 860-872 (2006)
  7. Opportunities for structure-based design of protease-directed drugs. Mittl PR, Grütter MG. Curr. Opin. Struct. Biol. 16 769-775 (2006)
  8. Neuropeptidases and the metabolic inactivation of insect neuropeptides. Isaac RE, Bland ND, Shirras AD. Gen. Comp. Endocrinol. 162 8-17 (2009)
  9. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors. Patel BD, Ghate MD. Eur J Med Chem 74 574-605 (2014)
  10. Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes. Lacroix IM, Li-Chan EC. Mol Nutr Food Res 58 61-78 (2014)
  11. Covalent inhibitors design and discovery. De Cesco S, Kurian J, Dufresne C, Mittermaier AK, Moitessier N. Eur J Med Chem 138 96-114 (2017)
  12. Food protein-derived bioactive peptides in management of type 2 diabetes. Patil P, Mandal S, Tomar SK, Anand S. Eur J Nutr 54 863-880 (2015)
  13. Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors. Zettl H, Schubert-Zsilavecz M, Steinhilber D. ChemMedChem 5 179-185 (2010)
  14. Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. Trzaskalski NA, Fadzeyeva E, Mulvihill EE. Clin Med Insights Endocrinol Diabetes 13 1179551420912972 (2020)
  15. Activity and selectivity cliffs for DPP-IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening. Ojeda-Montes MJ, Gimeno A, Tomas-Hernández S, Cereto-Massagué A, Beltrán-Debón R, Valls C, Mulero M, Pujadas G, Garcia-Vallvé S. Med Res Rev 38 1874-1915 (2018)
  16. Dipeptidyl peptidase 9 substrates and their discovery: current progress and the application of mass spectrometry-based approaches. Wilson CH, Zhang HE, Gorrell MD, Abbott CA. Biol. Chem. 397 837-856 (2016)
  17. Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase? Juillerat-Jeanneret L, Tafelmeyer P, Golshayan D. Expert Opin. Ther. Targets 21 977-991 (2017)
  18. Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus. Liu D, Gao H, Tang W, Nie S. Ann. N. Y. Acad. Sci. 1401 28-36 (2017)
  19. Antidiabetic Food-Derived Peptides for Functional Feeding: Production, Functionality and In Vivo Evidences. Rivero-Pino F, Espejo-Carpio FJ, Guadix EM. Foods 9 (2020)
  20. Characteristics of Food Protein-Derived Antidiabetic Bioactive Peptides: A Literature Update. Nong NTP, Hsu JL. Int J Mol Sci 22 9508 (2021)
  21. Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology. Sebastián-Martín A, Sánchez BG, Mora-Rodríguez JM, Bort A, Díaz-Laviada I. Biomedicines 10 2026 (2022)
  22. Using Dictyostelium to Develop Therapeutics for Acute Respiratory Distress Syndrome. Kirolos SA, Rijal R, Consalvo KM, Gomer RH. Front Cell Dev Biol 9 710005 (2021)

Articles citing this publication (76)

  1. Structural and mechanistic analysis of two prolyl endopeptidases: role of interdomain dynamics in catalysis and specificity. Shan L, Mathews II, Khosla C. Proc Natl Acad Sci U S A 102 3599-3604 (2005)
  2. Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. Girardi AC, Knauf F, Demuth HU, Aronson PS. Am. J. Physiol., Cell Physiol. 287 C1238-45 (2004)
  3. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T. Biochem. Biophys. Res. Commun. 434 191-196 (2013)
  4. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Aertgeerts K, Ye S, Tennant MG, Kraus ML, Rogers J, Sang BC, Skene RJ, Webb DR, Prasad GS. Protein Sci. 13 412-421 (2004)
  5. Dipeptidyl peptidase-IV inhibitory peptides generated by tryptic hydrolysis of a whey protein concentrate rich in β-lactoglobulin. Silveira ST, Martínez-Maqueda D, Recio I, Hernández-Ledesma B. Food Chem 141 1072-1077 (2013)
  6. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Bjelke JR, Christensen J, Nielsen PF, Branner S, Kanstrup AB, Wagtmann N, Rasmussen HB. Biochem. J. 396 391-399 (2006)
  7. Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus. Ziarek JJ, Veldkamp CT, Zhang F, Murray NJ, Kartz GA, Liang X, Su J, Baker JE, Linhardt RJ, Volkman BF. J. Biol. Chem. 288 737-746 (2013)
  8. Aminomethylpyrimidines as novel DPP-IV inhibitors: a 10(5)-fold activity increase by optimization of aromatic substituents. Peters JU, Weber S, Kritter S, Weiss P, Wallier A, Boehringer M, Hennig M, Kuhn B, Loeffler BM. Bioorg. Med. Chem. Lett. 14 1491-1493 (2004)
  9. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. Edosada CY, Quan C, Tran T, Pham V, Wiesmann C, Fairbrother W, Wolf BB. FEBS Lett. 580 1581-1586 (2006)
  10. Concerted structural changes in the peptidase and the propeller domains of prolyl oligopeptidase are required for substrate binding. Szeltner Z, Rea D, Juhász T, Renner V, Fülöp V, Polgár L. J. Mol. Biol. 340 627-637 (2004)
  11. Homology models of dipeptidyl peptidases 8 and 9 with a focus on loop predictions near the active site. Rummey C, Metz G. Proteins 66 160-171 (2007)
  12. Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Kim YB, Kopcho LM, Kirby MS, Hamann LG, Weigelt CA, Metzler WJ, Marcinkeviciene J. Arch. Biochem. Biophys. 445 9-18 (2006)
  13. Induced-fit mechanism for prolyl endopeptidase. Li M, Chen C, Davies DR, Chiu TK. J. Biol. Chem. 285 21487-21495 (2010)
  14. Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins. Lacroix IM, Li-Chan EC. Peptides 54 39-48 (2014)
  15. Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV. Bjelke JR, Christensen J, Branner S, Wagtmann N, Olsen C, Kanstrup AB, Rasmussen HB. J. Biol. Chem. 279 34691-34697 (2004)
  16. A novel SUMO1-specific interacting motif in dipeptidyl peptidase 9 (DPP9) that is important for enzymatic regulation. Pilla E, Möller U, Sauer G, Mattiroli F, Melchior F, Geiss-Friedlander R. J. Biol. Chem. 287 44320-44329 (2012)
  17. Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. Barsun M, Jajcanin N, Vukelić B, Spoljarić J, Abramić M. Biol. Chem. 388 343-348 (2007)
  18. Rigidity and flexibility of dipeptidyl peptidase IV: crystal structures of and docking experiments with DPIV. Engel M, Hoffmann T, Manhart S, Heiser U, Chambre S, Huber R, Demuth HU, Bode W. J. Mol. Biol. 355 768-783 (2006)
  19. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. Hiramatsu H, Yamamoto A, Kyono K, Higashiyama Y, Fukushima C, Shima H, Sugiyama S, Inaka K, Shimizu R. Biol. Chem. 385 561-564 (2004)
  20. How the Same Core Catalytic Machinery Catalyzes 17 Different Reactions: the Serine-Histidine-Aspartate Catalytic Triad of α/β-Hydrolase Fold Enzymes. Rauwerdink A, Kazlauskas RJ. ACS Catal 5 6153-6176 (2015)
  21. A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2. Xi CR, Di Fazio A, Nadvi NA, Patel K, Xiang MSW, Zhang HE, Deshpande C, Low JKK, Wang XT, Chen Y, McMillan CLD, Isaacs A, Osborne B, Vieira de Ribeiro AJ, McCaughan GW, Mackay JP, Church WB, Gorrell MD. Molecules 25 E5392 (2020)
  22. The reversed binding of beta-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Nordhoff S, Cerezo-Gálvez S, Feurer A, Hill O, Matassa VG, Metz G, Rummey C, Thiemann M, Edwards PJ. Bioorg. Med. Chem. Lett. 16 1744-1748 (2006)
  23. Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex. Kumar M, Prashar V, Mahale S, Hosur MV. Biochem. J. 389 365-371 (2005)
  24. Purification and characterization of human prolyl dipeptidase DPP8 in Sf9 insect cells. Chen YS, Chien CH, Goparaju CM, Hsu JT, Liang PH, Chen X. Protein Expr. Purif. 35 142-146 (2004)
  25. The dimeric transmembrane domain of prolyl dipeptidase DPP-IV contributes to its quaternary structure and enzymatic activities. Chung KM, Cheng JH, Suen CS, Huang CH, Tsai CH, Huang LH, Chen YR, Wang AH, Jiaang WT, Hwang MJ, Chen X. Protein Sci. 19 1627-1638 (2010)
  26. 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA. Zeng J, Liu G, Tang Y, Jiang H. J Mol Model 13 993-1000 (2007)
  27. Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Taldone T, Zito SW, Talele TT. Bioorg. Med. Chem. Lett. 18 479-484 (2008)
  28. Molecular cloning of the precursor polypeptide of mastoparan B and its putative processing enzyme, dipeptidyl peptidase IV, from the black-bellied hornet, Vespa basalis. Lee VS, Tu WC, Jinn TR, Peng CC, Lin LJ, Tzen JT. Insect Mol. Biol. 16 231-237 (2007)
  29. Degradation and Stabilization of Peptide Hormones in Human Blood Specimens. Yi J, Warunek D, Craft D. PLoS ONE 10 e0134427 (2015)
  30. Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors. Kang NS, Ahn JH, Kim SS, Chae CH, Yoo SE. Bioorg. Med. Chem. Lett. 17 3716-3721 (2007)
  31. Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV. Hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV. Cohen M, Fruitier-Arnaudin I, Piot JM. Biochimie 86 31-37 (2004)
  32. Structures of human DPP7 reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases. Bezerra GA, Dobrovetsky E, Dong A, Seitova A, Crombett L, Shewchuk LM, Hassell AM, Sweitzer SM, Sweitzer TD, McDevitt PJ, Johanson KO, Kennedy-Wilson KM, Cossar D, Bochkarev A, Gruber K, Dhe-Paganon S. PLoS ONE 7 e43019 (2012)
  33. Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. Huang CH, Suen CS, Lin CT, Chien CH, Lee HY, Chung KM, Tsai TY, Jiaang WT, Hwang MJ, Chen X. J. Biochem. 149 685-692 (2011)
  34. Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. Watanabe YS, Yasuda Y, Kojima Y, Okada S, Motoyama T, Takahashi R, Oka M. J Enzyme Inhib Med Chem 30 981-988 (2015)
  35. Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides. Lacroix IM, Li-Chan EC. Peptides 69 19-25 (2015)
  36. Decoding the structural events in substrate-gating mechanism of eukaryotic prolyl oligopeptidase using normal mode analysis and molecular dynamics simulations. Kaushik S, Etchebest C, Sowdhamini R. Proteins 82 1428-1443 (2014)
  37. His507 of acylaminoacyl peptidase stabilizes the active site conformation, not the catalytic intermediate. Kiss AL, Szeltner Z, Fülöp V, Polgár L. FEBS Lett. 571 17-20 (2004)
  38. Novel inhibitor for prolyl tripeptidyl aminopeptidase from Porphyromonas gingivalis and details of substrate-recognition mechanism. Xu Y, Nakajima Y, Ito K, Zheng H, Oyama H, Heiser U, Hoffmann T, Gärtner UT, Demuth HU, Yoshimoto T. J. Mol. Biol. 375 708-719 (2008)
  39. Synthesis and biological activity of sulphostin analogues, novel dipeptidyl peptidase IV inhibitors. Abe M, Akiyama T, Umezawa Y, Yamamoto K, Nagai M, Yamazaki H, Ichikawa Y, Muraoka Y. Bioorg. Med. Chem. 13 785-797 (2005)
  40. A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors. Hu CX, Huang H, Zhang L, Huang Y, Shen ZF, Cheng KD, Du GH, Zhu P. Biotechnol. Lett. 31 979-984 (2009)
  41. Dipeptidyl peptidase IV inhibitory peptides generated in Spanish dry-cured ham. Gallego M, Aristoy MC, Toldrá F. Meat Sci. 96 757-761 (2014)
  42. Generation of dipeptidyl peptidase-IV-inhibiting peptides from β-lactoglobulin secreted by Lactococcus lactis. Shigemori S, Oshiro K, Wang P, Yamamoto Y, Wang Y, Sato T, Uyeno Y, Shimosato T. Biomed Res Int 2014 393598 (2014)
  43. Molecular docking studies and 2D analyses of DPP-4 inhibitors as candidates in the treatment of diabetes. Pantaleão SQ, Maltarollo VG, Araujo SC, Gertrudes JC, Honorio KM. Mol Biosyst 11 3188-3193 (2015)
  44. S46 peptidases are the first exopeptidases to be members of clan PA. Sakamoto Y, Suzuki Y, Iizuka I, Tateoka C, Roppongi S, Fujimoto M, Inaka K, Tanaka H, Masaki M, Ohta K, Okada H, Nonaka T, Morikawa Y, Nakamura KT, Ogasawara W, Tanaka N. Sci Rep 4 4977 (2014)
  45. The structural comparison of the bacterial PepX and human DPP-IV reveals sites for the design of inhibitors of PepX activity. Rigolet P, Xi XG, Rety S, Chich JF. FEBS J. 272 2050-2059 (2005)
  46. Dipeptidyl peptidase IV activity in commercial solutions of human serum albumin. Bar-Or D, Slone DS, Mains CW, Rael LT. Anal. Biochem. 441 13-17 (2013)
  47. Exceptional diversity and selection pressure on coronavirus host receptors in bats compared to other mammals. Frank HK, Enard D, Boyd SD. Proc Biol Sci 289 20220193 (2022)
  48. Flavanol concentrations do not predict dipeptidyl peptidase-IV inhibitory activities of four cocoas with different processing histories. Ryan CM, Khoo W, Stewart AC, O'Keefe SF, Lambert JD, Neilson AP. Food Funct 8 746-756 (2017)
  49. Functional similarities between the dictyostelium protein AprA and the human protein dipeptidyl-peptidase IV. Herlihy SE, Tang Y, Phillips JE, Gomer RH. Protein Sci. 26 578-585 (2017)
  50. Possible ligand release pathway of dipeptidyl peptidase IV investigated by molecular dynamics simulations. Li C, Shen J, Li W, Lu C, Liu G, Tang Y. Proteins 79 1800-1809 (2011)
  51. Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer. Ross B, Krapp S, Augustin M, Kierfersauer R, Arciniega M, Geiss-Friedlander R, Huber R. Proc. Natl. Acad. Sci. U.S.A. 115 E1437-E1445 (2018)
  52. A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein. Schnapp G, Hoevels Y, Bakker RA, Schreiner P, Klein T, Nar H. ChemMedChem 16 630-639 (2021)
  53. Catalytically distinct states captured in a crystal lattice: the substrate-bound and scavenger states of acylaminoacyl peptidase and their implications for functionality. Menyhárd DK, Orgován Z, Szeltner Z, Szamosi I, Harmat V. Acta Crystallogr. D Biol. Crystallogr. 71 461-472 (2015)
  54. Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues. Roppongi S, Suzuki Y, Tateoka C, Fujimoto M, Morisawa S, Iizuka I, Nakamura A, Honma N, Shida Y, Ogasawara W, Tanaka N, Sakamoto Y, Nonaka T. Sci Rep 8 2714 (2018)
  55. Identification and partial characterization of the enzyme of omega: one of five putative DPP IV genes in Drosophila melanogaster. Chihara CJ, Song C, LaMonte G, Fetalvero K, Hinchman K, Phan H, Pineda M, Robinson K, Schneider GP. J. Insect Sci. 5 26 (2005)
  56. Inhibition of Dipeptidyl Peptidase-4 by Flavonoids: Structure-Activity Relationship, Kinetics and Interaction Mechanism. Pan J, Zhang Q, Zhang C, Yang W, Liu H, Lv Z, Liu J, Jiao Z. Front Nutr 9 892426 (2022)
  57. Monitoring of the effects of transfection with baculovirus on Sf9 cell line and expression of human dipeptidyl peptidase IV. Ustün-Aytekin O, Gürhan ID, Ohura K, Imai T, Ongen G. Cytotechnology 66 159-168 (2014)
  58. Probing prime substrate binding sites of human dipeptidyl peptidase-IV using competitive substrate approach. Kopcho LM, Kim YB, Wang A, Liu MA, Kirby MS, Marcinkeviciene J. Arch. Biochem. Biophys. 436 367-376 (2005)
  59. Protease activated-receptor 2 is necessary for neutrophil chemorepulsion induced by trypsin, tryptase, or dipeptidyl peptidase IV. White MJV, Chinea LE, Pilling D, Gomer RH. J. Leukoc. Biol. 103 119-128 (2018)
  60. Screening for Potential Novel Probiotics With Dipeptidyl Peptidase IV-Inhibiting Activity for Type 2 Diabetes Attenuation in vitro and in vivo. Yan F, Li N, Yue Y, Wang C, Zhao L, Evivie SE, Li B, Huo G. Front Microbiol 10 2855 (2019)
  61. Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP). Bainbridge TW, Dunshee DR, Kljavin NM, Skelton NJ, Sonoda J, Ernst JA. Sci Rep 7 12524 (2017)
  62. Crystal structures of human dipeptidyl peptidase IV in its apo and diprotin B-complexed forms. Hiramatsu H, Kyono K, Yamamoto A, Saeki K, Shima H, Sugiyama S, Inaka K, Shimizu R. Acta Biochim. Biophys. Sin. (Shanghai) 39 335-343 (2007)
  63. Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases. Kong F, Pang X, Zhao J, Deng P, Zheng M, Zhong D, Chen X. Drug Metab Dispos 47 238-248 (2019)
  64. Hydrophobic interactions at subsite S1' of human dipeptidyl peptidase IV contribute significantly to the inhibitory effect of tripeptides. Araki M, Kanegawa N, Iwata H, Sagae Y, Ito K, Masuda K, Okuno Y. Heliyon 6 e04227 (2020)
  65. Isolation of dipeptidyl peptidase IV (DP 4) isoforms from porcine kidney by preparative isoelectric focusing to improve crystallization. Wagner L, Wermann M, Rosche F, Rahfeld JU, Hoffmann T, Demuth HU. Biol. Chem. 392 665-677 (2011)
  66. Response surface methodology applied to the generation of casein hydrolysates with antioxidant and dipeptidyl peptidase IV inhibitory properties. Nongonierma AB, Maux SL, Esteveny C, FitzGerald RJ. J. Sci. Food Agric. 97 1093-1101 (2017)
  67. An Observational Study showing Dipeptidyl Peptidase-4 (DPP-4) Activity and Gene Expression Variation in Chronic Liver Disease (CLD) Patients from a Tertiary Care Hospital of Eastern India. Barkondaj B, Nargis T, Chakrabarti P, Mukhopadhyay S, Biswas K, Ganguly D, Chaterjee C, Sengupta N, Hazra A. Indian J Endocrinol Metab 26 245-251 (2022)
  68. In Silico Prospecting for Novel Bioactive Peptides from Seafoods: A Case Study on Pacific Oyster (Crassostrea gigas). Zhou L, Mendez RL, Kwon JY. Molecules 28 651 (2023)
  69. Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients. Sarkar J, Nargis T, Tantia O, Ghosh S, Chakrabarti P. Front Endocrinol (Lausanne) 10 505 (2019)
  70. Investigation of Chlorella pyrenoidosa Protein as a Source of Novel Angiotensin I-Converting Enzyme (ACE) and Dipeptidyl Peptidase-IV (DPP-IV) Inhibitory Peptides. Li Y, Aiello G, Fassi EMA, Boschin G, Bartolomei M, Bollati C, Roda G, Arnoldi A, Grazioso G, Lammi C. Nutrients 13 1624 (2021)
  71. Novel hit of DPP-4Is as promising antihyperglycemic agents with dual antioxidant/anti-inflammatory effects for type 2 diabetes with/without COVID-19. Mahgoub S, Fatahala SS, Sayed AI, Atya HB, El-Shehry MF, Afifi H, Awad SM, El-Hameed RHA, Taha H. Bioorg Chem 128 106092 (2022)
  72. One Health and Cattle Genetic Resources: Mining More than 500 Cattle Genomes to Identify Variants in Candidate Genes Potentially Affecting Coronavirus Infections. Bovo S, Schiavo G, Fontanesi L. Animals (Basel) 12 838 (2022)
  73. Protection against Oxidative Stress and Metabolic Alterations by Synthetic Peptides Derived from Erythrina edulis Seed Protein. Rodríguez-Arana N, Jiménez-Aliaga K, Intiquilla A, León JA, Flores E, Zavaleta AI, Izaguirre V, Solis-Calero C, Hernández-Ledesma B. Antioxidants (Basel) 11 2101 (2022)
  74. Rational Design by Structural Biology of Industrializable, Long-Acting Antihyperglycemic GLP-1 Receptor Agonists. Sun L, Zheng ZM, Shao CS, Zhang ZY, Li MW, Wang L, Wang H, Zhao GH, Wang P. Pharmaceuticals (Basel) 15 740 (2022)
  75. Structural Dynamics of DPP-4 and Its Influence on the Projection of Bioactive Ligands. Pantaleão SQ, Philot EA, de Resende-Lara PT, Lima AN, Perahia D, Miteva MA, Scott AL, Honorio KM. Molecules 23 (2018)
  76. The Influence of Whey Protein Heating Parameters on Their Susceptibility to Digestive Enzymes and the Antidiabetic Activity of Hydrolysates. Bunsroem K, Prinyawiwatkul W, Thaiudom S. Foods 11 829 (2022)


Quick links